Binding of Harmine Derivatives to DNA: A Spectroscopic Investigation

Bruno Pagano 1, Marco Caterino 1, Rosanna Filosa 2 and Concetta Giancola 1,*

1 Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy; bruno.pagano@unina.it (B.P.); marco.caterino@unina.it (M.C.)
2 Department of Experimental Medicine, Campania University “Luigi Vanvitelli”, Via L. De Crecchio 7, 80138 Naples, Italy; rosanna.filosa@unicampania.it
* Correspondence: giancola@unina.it; Tel.: +39-081-674266

Received: 28 September 2017; Accepted: 24 October 2017; Published: 27 October 2017

Abstract: Harmine belongs to a group of β-carboline alkaloids endowed with antitumor properties. Harmine and its derivatives are thought to bind to DNA and interfere with topoisomerase activities. We investigated the base-dependent binding of harmine, and three of its synthetic anticancer-active derivatives to the genomic DNA from calf thymus and two synthetic 20-mer double helices, the poly(dG-dC)·poly(dG-dC) and the poly(dA-dT)·poly(dA-dT), by means of UV-Vis and circular dichroism (CD) spectroscopies. The data show that the DNA binding and stabilising properties of the investigated derivatives are base pair-dependent. These results could be used as a guide to design and develop further bioactive analogues.

Keywords: alkaloids; DNA duplex; spectroscopy

1. Introduction

Harmine (HR) is a widespread natural tricyclic β-carboline alkaloid, isolated from the seeds of Peganum harmala, a middle-eastern plant that has been known about for a long time and used in folk medicine [1–3]. Its structure is characterised by a pyridine ring fused to an indolyl ring, a methyl and a methoxy group at positions 1 and 7, respectively. Regardless of popular beliefs, there is a kernel of truth in the supposed beneficial effects of HR as it was proved to possess many very interesting properties, including antimicrobial, antioxidative, antitumor, anti-inflammatory, cytotoxic activity, and more [4–12]. It goes without saying that the anticancer property has emerged as the foremost alluring facet, prompting many groups to dedicate their efforts to synthesising harmine derivatives with enhanced antitumor properties against human cancer-cells [11,13,14].

The HR antiproliferative mechanism of action is far from being fully disclosed but it has become clear that the DNA intercalation is a driving force. HR is mainly known to interfere with the DNA topoisomerase activity [15], but also to induce DNA damage [16], and to inhibit the telomerase that leads to cell senescence [17]. The key factors are the HR tricyclic planar molecular geometry and identities and arrangement of its substituents [14,18,19].

To achieve a deeper understanding of the HR-derivatives binding to the DNA, herein we report a UV/Vis- and CD-based investigation of the DNA-binding properties of three synthetic HR derivatives (compounds I–III, Figure 1), which were previously proved to have enhanced activity against human prostate cancer cells (PC-3) in the µM range [14]. The joint UV/Vis-circular dichroism approach is widely adopted for studying DNA-ligand systems [18,20,21]. It is readily diagnostic of the ligand-DNA interaction and of the ensuing stabilisation effects, as well as for the binding-induced structural perturbations. Last and by no means least, the required sample amount is modest compared to other techniques. Calf thymus DNA (ctDNA) was used as a reference, and two synthetic 20-mer
duplexes were investigated for assessing the differential behaviour against GC and AT segments: the poly(dG-dC)-poly(dG-dC), hereafter d(GC)\textsubscript{10}, and the poly(dA-dT)-poly(dA-dT), referred to as d(AT)\textsubscript{10} from now on.

![Harmine and derivatives](image-url)

**Figure 1.** Chemical structure of harmine (7-methoxy-1-methyl-9H-pyrido[3,4-b]indole), and its synthetic derivatives: I (4-methoxy-1-methyl-9H-pyrido[3,4-b]indole), II (4-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole), and III (3-benzyl-1-methoxy-6-oxo-6H-indole[3,2,1-de]-[1,5]-naphthyridin-3-ium bromide).

On a structural basis, I differs from HR in the methoxy group at position 4 rather than 7. Compound II has an additional methyl group at position 9 with respect to I, whereas III features a fourth ring fused to the β-carboline structure, with a methoxy in position 4 and a benzyl group bound to the pyridine nitrogen (Figure 1).

2. Results

2.1. UV-Vis

The interaction between the investigated compounds and the DNA was analysed by UV-Vis spectroscopy. First, UV melting curves of the ctDNA at increasing HR concentration were recorded to evaluate the HR binding and stabilising capability. Harmine sizeably stabilises the ctDNA even at the 0.10 [harmine]:[ctDNA]\textsubscript{bp} ratio, whereas only a slight difference occurs between the UV thermal denaturation profiles at [harmine]:[ctDNA]\textsubscript{bp} ratios of 0.33 and 0.50, with the latter showing the maximum stabilizing effect ($\Delta T_m = 20 \text{ °C}$) (Figure 2a). The 0.50 ratio was thereby picked as a standard for the measures to follow, for studying the interaction between HR and its synthetic derivatives with either ctDNA, d(GC)\textsubscript{10} or d(AT)\textsubscript{10}.

As Figure 2b depicts and Table 1 summarises, UV melting data clearly show that each of the ligands stabilises the ctDNA [22]. Harmine works better than I and II, although, interestingly, the melting profile of the ctDNA with III exhibits two inflection points.

![UV-Vis melting profiles](image-url)

**Figure 2.** Normalised UV-Vis thermal melting profiles of Calf thymus DNA (ctDNA) at increasing [HR]:[ctDNA]\textsubscript{bp} ratio (a); and at [ligand]:[ctDNA]\textsubscript{bp} of 0.50 (b). The ligand concentrations were increased over a fixed (ctDNA)\textsubscript{bp}. Melting curves were obtained monitoring the absorbance at 260 nm as a function of temperature.
Table 1. Melting temperatures of the ctDNA, d(GC)\textsubscript{10}, and d(AT)\textsubscript{10} in the absence and presence of harmine, \textit{I}, \textit{II}, and \textit{III} at 0.50 [ligand]:[DNA]\textsubscript{bp} ratio obtained by UV melting experiments.

| Ligand | ctDNA | d(GC)\textsubscript{10} | d(AT)\textsubscript{10} |
|--------|-------|----------------|----------------|
| No ligand | 55    | >85 | 35 |
| Harmine | 75    | >85 | 45 |
| \textit{I} | 62    | >85 | 52 |
| \textit{II} | 65    | >85 | 52 |
| \textit{III} | ≈60–≈82 | >90 | 42 |

Figure 3 shows the UV-Vis spectra of both the free and ctDNA-bound ligands, which all intensely absorb in the 240–300 nm region and lesser in the 300–400 nm range. Each experimental ligand-ctDNA spectrum sizeably differs from the corresponding arithmetical ligand-ctDNA sum, highlighting the ligand-ctDNA interaction.

Figure 3. UV absorption spectra of the ctDNA with (a) harmine; (b) \textit{I}; (c) \textit{II}; and (d) \textit{III}. The arithmetical ligand-ctDNA sum spectra are reported as well.

Further base-dependent information came from the melting experiments performed with either d(GC)\textsubscript{10} (Figure 4a) or d(AT)\textsubscript{10} (Figure 4b). The melting temperatures in the case of d(AT)\textsubscript{10} complexes are well detected. On the contrary, the \( T_m \) values of the d(GC)\textsubscript{10} complexes are invariably higher than \( 80 \) °C, but not accurately measured due to the upper heating limit both in the absence and in the presence of the ligands, as already reported in the case with GC sequences in similar experimental conditions \[20,21\]. In any case, \textit{III} clearly makes the most stable complex with the d(GC)\textsubscript{10}, bearing witness to the key role that the benzyl group at position 3 and/or the fourth ring have in the interaction with GC-rich segments (Figure 3a and Table 1). In the case of d(AT)\textsubscript{10} (Figure 4b), the utmost stabilisation was achieved with both \textit{I} and \textit{II}, whereas \textit{III} and HR affect the \( T_m \) to a smaller extent.
2.2. Circular Dichroism

Circular dichroism (CD) spectroscopy was also employed for gaining insights into the conformational changes occurring upon β-carboline alkaloids binding to the DNA. Figure 5a shows the CD spectra of the ligand-free and ligand-bound ctDNA ([ligand]:[ctDNA]bp). The addition of HR, II or III extensively affects the ctDNA CD spectrum in the 240–300 nm interval, while minor changes occur upon the administration of III. New induced dichroic signals (ICD) arise in the 300–400 nm region purely due to the complex formation, since neither the DNA nor any of the ligands absorb in this range. The iCDs arise in the 300–400 nm range for all the complexes except for the one involving III.

Figure 4. Normalised UV thermal denaturation curves of d(GC)_{10} (a) and d(AT)_{10} (b) in the absence and presence of ligands at 0.50 [ligand]:[DNA]_{bp} ratio followed at 260 nm.

Figure 5. Circular dichroism spectra of (a) ctDNA; (b) d(GC)_{10}; and (c) d(AT)_{10}, either free or as bound at 0.50 [ligand]:[DNA]_{bp} ratio to the harmine or its three derivatives.
The iCD finds root in the transition moments coupling of both the ligand and the surrounding environs by the DNA, that is to say the reciprocal molecular orientation. While the iCD magnitude can hardly be accounted for, its sign relies strongly on the orientation of the ligand with respect to the DNA at the binding site [23,24]. This means the ligands can intercalate along the DNA axis as they are all oriented in parallel planes or alternately flipped each other. The former case prompts a net CD signal as seen for compounds I and II, whereas the latter might be the case with compound III where positive and negative contributions elide each other.

The binding effects of HR, I, II, and III on the CD spectra of d(GC)\textsubscript{10} and d(AT)\textsubscript{10} are shown in Figure 5b,c. The CD spectrum of the d(GC)\textsubscript{10} is markedly affected by all the ligands and, again, iCDs in the 300–400 nm region appear, with the exception of the complex made by III.

The CD spectrum of d(AT)\textsubscript{10} is instead slightly modified by each of the ligands in the 240–340 nm range yet no iCDs are detected in this case (Figure 5c).

3. Discussion

The harmine-derivatives family is very alluring for many purposes, including cancer treatment. The comprehension of the mechanism of action, however, still has blind spots, although the intercalation into DNA duplex is known to be responsible for hampering the DNA replication. Synthetic harmine derivatives were proved to have enhanced antitumor properties according to their molecular geometry and substituents configuration. Little is known about the sequence-specific interaction of these compounds with the DNA and harmine was only recently demonstrated to preferentially bind GC-rich segments [25].

We investigated the interaction of calf thymus DNA and of the d(GC)\textsubscript{10} and d(AT)\textsubscript{10} 20-mer duplexes with both harmine and three of its derivatives (compounds I–III), which recently were proved to have enhanced anticancer activity [14].

UV-Vis absorption confirms all the ligands to stabilise the ctDNA sequence in the order HR > II > I (Table 1). Sequence-specific behaviours were found as the d(AT)\textsubscript{10} is greatly stabilised by both I and II (ΔT\textsubscript{m} = +17 °C) and to a smaller extent by HR and III (ΔT\textsubscript{m} = +10 and +7 °C, respectively). In contrast, compound III clearly makes the most stable d(GC)\textsubscript{10} complex though the upper heating limit, which prevented us from pinpointing the T\textsubscript{m} values. This is consistent with previous findings in resembling experimental conditions [20,21]. In contrast, I and II barely affect the T\textsubscript{m} of the GC-rich fragment. Notably, the UV thermal denaturation profile of ctDNA in the presence of compound III exhibits two inflection points. The more complex ctDNA thermal denaturation process as compared to monotonous 20-mer sequences can make this intelligible. The ctDNA features both AT- and GC-rich shuffled segments that undergo differential thermal denaturation. In terms of T\textsubscript{m}, compound III has a much weaker effect on AT segments countered by the very strong impact on the GC stretches thereby introducing a massive T\textsubscript{m} gap between the two, which detectable by our UV investigation. In contrast, the much smaller behaviour bias that HR, I, and II exhibit towards AT and GC results in narrower T\textsubscript{m} splitting, which is conceivably undetectable in a UV melting study, at least in these experimental conditions. Comparable two-inflection UV thermal profile had been reported for a 9-benzyl-substituted harmine derivative compound [18].

Given these findings, cautious structural consideration can be drawn. Although precise ΔT\textsubscript{m} are not available for the d(GC)\textsubscript{10}, the methoxy group position switch from 7 to 4 appears to hinder the d(GC)\textsubscript{10} stability while sensibly hardening the d(AT)\textsubscript{10} at a comparison of the melting profiles of HR and I reported in Figure 4a,b. No stabilising effect to d(AT)\textsubscript{10} is appreciable upon addition of the methyl group at position 9, whereas the d(GC)\textsubscript{10} thermal profile is perturbed. Anyway, one could hypothesise a DNA pre-melting secondary structure transition as already seen for poly(dA-dT) poly(dA-dT) duplex [26,27]. As compared to harmine, the fourth ring with an extra H-bond acceptor, the benzyl group, and the static positive charge featured by III markedly enhance the d(GC)\textsubscript{10}-selective thermal stabilisation whilst even bearing reduced effectiveness on d(AT)\textsubscript{10}. 
Among the harmine derivatives previously addressed, compound III demonstrated the utmost antiproliferative capacity towards PC-3 cells [14]. Notably, many DNA-intercalating, anticancer-active drugs have indeed been reported to exhibit preferential binding to GC-rich segments, amid a long-lasting hypothesis of a positive correlation between in vivo antitumor activity and the preferential binding to GC-rich DNA sequences [28]. Given these findings and structural observations, III may serve as a hit-compound to start from for advancing the rational design of sequence-specific, DNA-intercalating, and anticancer-active small molecules.

4. Materials and Methods

4.1. Chemicals

The 4-methoxy-1-methyl-9H-pyrido(3,4-b)indole (I), the 4-methoxy-1,9-dimethyl-9H-pyrido (3,4-b)indole (II) and, the 3-benzyl-1-methoxy-6-oxo-6H-indole(3,2,1-de)-(1,5)-naphthyridin-3-ium (III) were synthesised according to procedures reported elsewhere [14]. Harmine and its derivatives were dissolved in DMSO. The calf thymus DNA and the 20-mer oligonucleotides were purchased from Sigma Aldrich (Milan, Italy) and biomers.net (biomers.net GmbH, Ulm, Germany), respectively. A 1 mM sodium phosphate, 0.1 mM EDTA buffer at pH 7.0 was used for dissolving the ctDNA and the d(GC)\(_{10}\), whereas a 40.0 mM sodium phosphate, 0.1 mM EDTA buffer at pH 7.0 was used for the d(AT)\(_{10}\). The ctDNA concentration was determined spectrophotometrically by using the molar extinction coefficient value (\(\lambda\) 260 nm) per base-pairs of 13,200 cm\(^{-1}\) M\(^{-1}\) [29]. The 20-mer d(GC)\(_{10}\) and d(AT)\(_{10}\) duplex concentrations were determined by the nearest-neighbour method using molar extinction coefficient values at \(\lambda\) 260 nm of 315,988 and 316,144 cm\(^{-1}\) M\(^{-1}\), respectively [30]. The per base-pair concentrations for the d(AT)\(_{10}\) and d(GC)\(_{10}\) were calculated by multiplying by twentyfold those of the respective duplex. MilliQ filtered water was used.

4.2. UV Measurements

UV-Vis absorption spectra were recorded by using a Jasco V-530 spectrometer (Jasco International Co., Tokyo, Japan) equipped with a PTC-348WI thermoelectrically controlled cell holder (Jasco International Co., Tokyo, Japan), at 10 °C for the d(AT)\(_{10}\) and 25 °C for ctDNA and d(GC)\(_{10}\) in the 400–230 nm range using twin quartz cells, 0.1 cm optical path. UV melting experiments were registered at 260 nm in the 25–95 °C range for the d(GC)\(_{10}\) and 10–80 °C for the d(AT)\(_{10}\), temperature ramp 1 °C min\(^{-1}\). The UV melting curves were normalised to the 0–1 range and melting temperatures calculated by first derivative.

4.3. CD Measurements

A Jasco J-715 spectropolarimeter (Jasco International Co., Tokyo, Japan) was used for circular dichroism measures by using a 0.1 cm path length cuvette in a Peltier-thermostatted cell holder at both 10 and 25 °C. The scan rate was 20 nm min\(^{-1}\) and bandwidth 2.0 nm. Spectra were collected in the 400–230 nm range and averaged over three collections.

**Acknowledgments:** This work was supported by “Finanziamento della Ricerca di Ateneo 2016” from the University of Naples Federico II (prot. No. 0016505 to C.G.) and by the Italian Association for Cancer Research (AIRC) (IG 16730 to B.P.).

**Author Contributions:** B.P. and C.G. conceived and designed the experiments; B.P. performed the experiments; B.P., M.C. and C.G. analysed the data; R.F. carried out the chemical synthesis of compounds; B.P., M.C. and C.G. wrote the paper.

**Conflicts of Interest:** The authors declare no conflict of interest.
References

1. Siddiqui, S.; Khan, O.Y.; Faizi, S.; Siddiqui, B.S. Studies on the chemical-constituents of the seeds of *Peganum harmala*. Isolation and structure of a new β-carboline alkaloid. Harmalicine. *Heterocycles* 1987, 26, 1563–1567. [CrossRef]

2. Siddiqui, S.; Khan, O.Y.; Faizi, S.; Siddiqui, B.S. Studies on the chemical-constituents of the seeds of *Peganum-harmala*: Isolation and structure elucidation of two β-carbolines—harmalacinine and norharmine. *Heterocycles* 1989, 29, 521–527. [CrossRef] [PubMed]

3. Moloudizargari, M.; Mikaili, P.; Aghajanshakeri, S.; Asghari, M.H.; Shayegh, J. Pharmacological and therapeutic effects of *Peganum harmala* and its main alkaloids. *Pharmacogn. Rev.* 2013, 7, 199–212. [CrossRef] [PubMed]

4. Zaker, F.; Oody, A.; Arjmand, A. A study on the antitumoral and differentiation effects of *Peganum harmala* derivatives in combination with ATRA on leukaemic cells. *Arch. Pharm. Res.* 2007, 30, 844–849. [CrossRef] [PubMed]

5. Egusa, H.; Doi, M.; Saeki, M.; Fukuyasu, S.; Akashi, Y.; Yokota, Y.; Yatani, H.; Kamisaki, Y. The small molecule harmine regulates nfatc1 and id2 expression in osteoclast progenitor cells. *Bone* 2011, 49, 264–274. [CrossRef] [PubMed]

6. Frost, D.; Meechoovet, B.; Wang, T.; Gately, S.; Giorgetti, M.; Shcherbakova, I.; Dunckley, T. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer’s disease-related sites. *PLoS ONE* 2011, 6, e19264. [CrossRef] [PubMed]

7. Hamsa, T.P.; Kuttan, G. Harmine activates intrinsic and extrinsic pathways of apoptosis in b16f-10 melanoma. *Chin. Med.* 2011, 6, 11. [CrossRef] [PubMed]

8. Yonezawa, T.; Hasegawa, S.; Asai, M.; Ninomiya, T.; Sasaki, T.; Cha, B.Y.; Teruya, T.; Ozawa, H.; Yagasaki, K.; Nagai, K.; et al. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo. *Eur. J. Pharmacol.* 2011, 650, 511–518. [CrossRef] [PubMed]

9. Onishi, Y.; Oishi, K.; Kawano, Y.; Yamazaki, Y. The harmala alkaloid harmine is a modulator of circadian Bmal1 transcription. *Biosci. Rep.* 2012, 32, 45–52. [CrossRef] [PubMed]

10. Reus, G.Z.; Stringari, R.B.; Goncalves, C.L.; Scaini, G.; Carvalho-Silva, M.; Jeremias, G.C.; Jeremias, I.C.; Ferreira, G.K.; Streck, E.L.; Hallak, J.E.; et al. Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain. *Depress. Res. Treat.* 2012, 2012, 987397. [CrossRef] [PubMed]

11. Yi, J.M.; Zhang, X.F.; Huan, X.J.; Song, S.S.; Wang, W.; Tian, Q.T.; Sun, Y.M.; Chen, Y.; Ding, J.; Wang, Y.Q.; et al. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition. *Oncotarget* 2015, 6, 8960–8973. [CrossRef] [PubMed]

12. Liu, X.; Li, M.; Tan, S.; Wang, C.; Fan, S.; Huang, C. Harmine is an inflammatory inhibitor through the suppression of NF-κB signaling. *Biochim. Biophys. Res. Commun.* 2017, 489, 332–338. [CrossRef] [PubMed]

13. Chen, Q.; Chao, R.; Chen, H.; HOU, X.; YAN, H.; ZHOU, S.; PENG, W.; XU, A. Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. *Int. J. Cancer* 2005, 114, 675–682. [CrossRef] [PubMed]

14. Peduto, A.; More, V.; de Caprariis, P.; Festa, M.; Capasso, A.; Piccente, S.; De Martino, L.; De Feo, V.; Filosa, R. Synthesis and cytotoxic activity of new β-carboline derivatives. *Mini Rev. Med. Chem.* 2011, 11, 486–491. [CrossRef] [PubMed]

15. Funayama, Y.; Nishio, K.; Wakabayashi, K.; Nagao, M.; Shimoi, K.; Ohira, T.; Hasegawa, S.; Sajio, N. Effects of β- and γ-carboline derivatives on DNA topoisomerase activities. *Mutat. Res.-Fund. Mol. Mech. Mutagen.* 1996, 349, 183–191. [CrossRef]

16. Wink, M.; Schimmer, O. Molecular modes of action of defensive secondary metabolites. In *Annual Plant Reviews Volume 39: Functions and Biotechnology of Plant Secondary Metabolites*; Wiley-Blackwell: Oxford, UK, 2010; pp. 21–161.

17. Zhao, L.; Wink, M. The β-carboline alkaloid harmine inhibits telomerase activity of MCF-7 cells by down-regulating hTERT mRNA expression accompanied by an accelerated senescent phenotype. *PeerJ* 2013, 1, e174. [CrossRef] [PubMed]

18. Cao, R.; Peng, W.; Chen, H.; Ma, Y.; Liu, X.; Hou, X.; Guan, H.; Xu, A. DNA binding properties of 9-substituted harmine derivatives. *Biochim. Biophys. Res. Commun.* 2005, 338, 1557–1563. [CrossRef] [PubMed]
19. Cao, R.; Peng, W.; Chen, H.; Hou, X.; Guan, H.; Chen, Q.; Ma, Y.; Xu, A. Synthesis and in vitro cytotoxic evaluation of 1,3-bisubstituted and 1,3,9-trisubstituted β-carboline derivatives. *Eur. J. Med. Chem.* **2005**, *40*, 249–257. [CrossRef] [PubMed]

20. Airoldi, M.; Barone, G.; Gennaro, G.; Giuliani, A.M.; Giustini, M. Interaction of doxorubicin with polynucleotides. A spectroscopic study. *Biochemistry* **2014**, *53*, 2197–2207. [CrossRef] [PubMed]

21. Bhadra, K.; Maiti, M.; Kumar, G.S. Molecular recognition of DNA by small molecules: At base pair specific intercalative binding of cytotoxic plant alkaloid palmatine. *Biochim. Biophys. Acta* **2007**, *1770*, 1071–1080. [CrossRef] [PubMed]

22. Mergny, J.L.; Lacroix, L. Analysis of thermal melting curves. *Oligonucleotides* **2003**, *13*, 515–537. [CrossRef] [PubMed]

23. Lyng, R.; Hard, T.; Norden, B. Induced CD of DNA intercalators: Electric dipole allowed transitions. *Biopolymers* **1987**, *26*, 1327–1345. [CrossRef] [PubMed]

24. Monnot, M.; Mauffret, O.; Lescot, E.; Fermandjian, S. Probing intercalation and conformational effects of the anticancer drug 2-methyl-9-hydroxyellipticinium acetate in DNA fragments with circular-dichroism. *Eur. J. Biochem.* **1992**, *204*, 1035–1039. [CrossRef] [PubMed]

25. Sharma, S.; Yadav, M.; Gupta, S.P.; Pandav, K.; Kumar, S. Spectroscopic and structural studies on the interaction of an anticancer β-carboline alkaloid, harmine with GC and AT specific DNA oligonucleotides. *Eur. J. Biochem.* **1992**, *204*, 1035–1039. [CrossRef] [PubMed]

26. Saha, I.; Hossain, M.; Kumar, G.S. Sequence-selective binding of phenazinium dyes phenosafranin and safranin O to guanine-cytosine deoxyribopolynucleotides: Spectroscopic and thermodynamic studies. *J. Phys. Chem.* B **2010**, *114*, 15278–15287. [CrossRef] [PubMed]

27. Herrera, J.E.; Chaires, J.B. A premelting conformational transition in poly(dA)-poly(dT) coupled to daunomycin binding. *Biochemistry* **1989**, *28*, 1993–2000. [CrossRef] [PubMed]

28. Schwaller, M.A.; Aubard, J.; Auclair, C.; Paoletti, C.; Dodin, G. The G.C base-pair preference of 2-N-methyl 9-hydroxyellipticinium. *Eur. J. Biochem.* **1989**, *181*, 129–134. [CrossRef] [PubMed]

29. Shehi, E.; Granata, V.; Del Vecchio, P.; Barone, G.; Fusi, P.; Tortora, P.; Graziano, G. Thermal stability and DNA binding activity of a variant form of the Sso7d protein from the archeon Sulfolobus solfataricus truncated at leucine 54. *Biochemistry* **2003**, *42*, 8362–8368. [CrossRef] [PubMed]

30. Cantor, C.R.; Warshaw, M.M.; Shapiro, H. Oligonucleotide interactions. III. Circular dichroism studies of the conformation of deoxyoligonucleotides. *Biopolymers* **1970**, *9*, 1059–1077. [CrossRef] [PubMed]

**Sample Availability:** Samples of the compounds I–III are available from authors.